RXi Pharmaceuticals Corp. of Worcester recently acquired direct ownership of technology from Advirna LLC, a small biotechnology company in Boulder, CO.
The technology is a method for delivering RNAi-based drugs into living organisms.
RXi specializes in the development and possible commercialization of drugs based on RNA interference, which has the potential to block the production of disease-causing proteins before they are made by the body.
Financial terms of the agreement were not disclosed.
